Anti-CD47 clone STI-6643 was affinity-engineered to exhibit reduced binding affinity towards its target with the hypothesis that avidity rather than affinity would drive target engagement and thus it would lower on-target off-tumor toxicity and improve bioavailability. This evidence concerns the gene CD47 and neoplasm.